Ashton Thomas Securities LLC Purchases 1,899 Shares of Novo Nordisk A/S (NYSE:NVO)

Ashton Thomas Securities LLC increased its position in shares of Novo Nordisk A/S (NYSE:NVO) by 20.8% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 11,024 shares of the company’s stock after buying an additional 1,899 shares during the quarter. Ashton Thomas Securities LLC’s holdings in Novo Nordisk A/S were worth $1,313,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. 1900 Wealth Management LLC raised its position in shares of Novo Nordisk A/S by 15.4% during the third quarter. 1900 Wealth Management LLC now owns 6,201 shares of the company’s stock valued at $796,000 after buying an additional 826 shares during the last quarter. Crossmark Global Holdings Inc. grew its position in Novo Nordisk A/S by 31.3% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 52,596 shares of the company’s stock worth $6,263,000 after acquiring an additional 12,539 shares during the last quarter. Costello Asset Management INC boosted its stake in Novo Nordisk A/S by 14.7% in the third quarter. Costello Asset Management INC now owns 29,680 shares of the company’s stock worth $3,534,000 after purchasing an additional 3,796 shares in the last quarter. Mesirow Financial Investment Management Inc. grew its holdings in shares of Novo Nordisk A/S by 7.0% during the third quarter. Mesirow Financial Investment Management Inc. now owns 11,610 shares of the company’s stock worth $1,382,000 after purchasing an additional 763 shares during the last quarter. Finally, RKL Wealth Management LLC increased its stake in shares of Novo Nordisk A/S by 0.5% in the third quarter. RKL Wealth Management LLC now owns 84,470 shares of the company’s stock valued at $10,058,000 after buying an additional 400 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. BMO Capital Markets decreased their price objective on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a report on Thursday, October 17th. StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $144.50.

Novo Nordisk A/S Stock Down 0.4 %

Shares of NYSE:NVO opened at $107.20 on Monday. The company has a 50 day moving average price of $121.42 and a two-hundred day moving average price of $130.31. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The company has a market capitalization of $481.06 billion, a PE ratio of 34.69, a PEG ratio of 1.48 and a beta of 0.42. Novo Nordisk A/S has a 52 week low of $94.73 and a 52 week high of $148.15.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.